Trials / Terminated
TerminatedNCT04889040
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7496998 | 275 mg tablets |
| DRUG | Placebo | Matching tablets |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2021-12-02
- Completion
- 2021-12-02
- First posted
- 2021-05-17
- Last updated
- 2024-01-05
- Results posted
- 2024-01-05
Locations
50 sites across 12 countries: Argentina, Belgium, Brazil, Denmark, Germany, Japan, Mexico, Portugal, Romania, Switzerland, Turkey (Türkiye), Ukraine
Source: ClinicalTrials.gov record NCT04889040. Inclusion in this directory is not an endorsement.